Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial.

Anticancer research - 1 Jul 2025

VAN Bussel Mark T J, Bravenboer Nathalie, Essen Huib VAN, Snaebjornsson Petur, Appelman-Dijkstra Natasha M, Schellens Jan Hm, Opdam Frans L

Abstract excerpt

BACKGROUND/AIM: More than 90% of colorectal cancers (CRC) have alterations in WNT signaling. Eight to ten percent of patients with metastatic Kirsten rat sarcoma virus - wild type (KRAS-WT) CRC have B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) mutations and do not benefit from epidermal growth factor receptor (EGFR) antibodies. The addition of a porcupine inhibitor could increase the response rate in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Clinical Trials, Phase I as Topic

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Wnt Proteins

Source

Identifiers

PMID: 40578933
DOI: 10.21873/anticanres.17677

Genes

KRAS
BRAF
EGFR
RNF43

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial.PMID 40578933Read ↗

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer.Semantic proximity Read ↗

Severe bone disease with bilateral femur fracture in a young woman after gastrectomy for gastric polyposis with SMAD4 mutation.Semantic proximity Read ↗

The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistanceSemantic proximity Read ↗

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.Semantic proximity Read ↗

Regorafenib in Bone Sarcoma: A Systematic Review and Meta-Analysis of Its Effectiveness and Safety in Cancer TreatmentSemantic proximity Read ↗

Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.Semantic proximity Read ↗

Clinical features and KRAS mutation in colorectal cancer with bone metastasis.Semantic proximity Read ↗

Tumor Syndromes That Include Bone Tumors: An Update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.